Literature DB >> 11152016

Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management.

T Gerber1, H Schomerus.   

Abstract

The pathogenesis of hepatic encephalopathy (HE) is unknown. Many theories have been proposed. Most established therapies are based on such theories but since no theory has have ever been proved, therapies have to be considered empiric. The spectrum of HE ranges from minimal cerebral functional deficits, which can only be found by sensitive psychometric tests, to coma with signs of decerebration. HE has arbitrarily been divided into stages. A number of precipitating factors are known and the first line of therapy should always be the elimination of these factors. The differential diagnosis includes all states of impaired consciousness and deficits in cerebral function in patients with chronic liver disease, and clinical and biochemical tests to differentiate are indicated. The therapeutic options for HE include: protein restriction only for a limited time in comatous patients; nonabsorbable antibiotics (aminoglycosides), which because of adverse effects are also limited to higher grades of HE: intestinal cleansing which is applicable in all degrees of HE; lactulose, branched chain aminoacids and ornithin aspartate which have been proven to be effective and can be applied long term in patients with lower grades of HE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11152016     DOI: 10.2165/00003495-200060060-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  114 in total

1.  Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure.

Authors:  A S Basile; R D Hughes; P M Harrison; Y Murata; L Pannell; E A Jones; R Williams; P Skolnick
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

2.  Somatosensory evoked potentials and number connection test in the detection of subclinical hepatic encephalopathy.

Authors:  C L Yen; Y F Liaw
Journal:  Hepatogastroenterology       Date:  1990-06

3.  High prevalence of sleep disturbance in cirrhosis.

Authors:  J Córdoba; J Cabrera; L Lataif; P Penev; P Zee; A T Blei
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

4.  Evidence for the role of ammonia in the intracerebral transfer and metabolism of tryptophan.

Authors:  P Grippon; M Le Poncin Lafitte; M Boschat; S Wang; G Faure; D Dutertre; P Opolon
Journal:  Hepatology       Date:  1986 Jul-Aug       Impact factor: 17.425

5.  Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma.

Authors:  L Zieve; W M Doizaki; J Zieve
Journal:  J Lab Clin Med       Date:  1974-01

6.  Hepatic encephalopathy: comparative study of EEG abnormalities, neuropsychic disturbances and blood ammonia.

Authors:  M Demedts; E Pillen; J De Groote; K P Van de Woestijne
Journal:  Acta Neurol Belg       Date:  1973 Sep-Oct       Impact factor: 2.396

7.  Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy.

Authors:  M Olasmaa; J D Rothstein; A Guidotti; R J Weber; S M Paul; S Spector; M L Zeneroli; M Baraldi; E Costa
Journal:  J Neurochem       Date:  1990-12       Impact factor: 5.372

Review 8.  Cerebral changes in hepatic encephalopathy.

Authors:  A Watanabe
Journal:  J Gastroenterol Hepatol       Date:  1998-07       Impact factor: 4.029

9.  The role of plasma amino acids in hepatic encephalopathy.

Authors:  J E Fischer; J M Funovics; A Aguirre; J H James; J M Keane; R I Wesdorp; N Yoshimura; T Westman
Journal:  Surgery       Date:  1975-09       Impact factor: 3.982

10.  Manganese and chronic hepatic encephalopathy.

Authors:  D Krieger; S Krieger; O Jansen; P Gass; L Theilmann; H Lichtnecker
Journal:  Lancet       Date:  1995-07-29       Impact factor: 79.321

View more
  22 in total

1.  Liver transplantation nearly normalizes brain spontaneous activity and cognitive function at 1 month: a resting-state functional MRI study.

Authors:  Yue Cheng; Lixiang Huang; Xiaodong Zhang; Jianhui Zhong; Qian Ji; Shuangshuang Xie; Lihua Chen; Panli Zuo; Long Jiang Zhang; Wen Shen
Journal:  Metab Brain Dis       Date:  2015-02-24       Impact factor: 3.584

2.  Multidimensional assessment of neuro-psychiatric symptoms in patients with low-grade hepatic encephalopathy: a clinical rating scale.

Authors:  Sergei Mechtcheriakov; Ivo-W Graziadei; André Kugener; Julia Wiedemann; Chantal Galbavy; Hartmann Hinterhuber; Josef Marksteiner; Wolfgang Vogel
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

Review 3.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Practical Issues in the Management of Overt Hepatic Encephalopathy.

Authors:  Ganesh Pantham; Kevin D Mullen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-11

5.  Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study.

Authors:  Claudia Sama; Antonio Maria Morselli-Labate; Paolo Pianta; Laura Lambertini; Sonia Berardi; Gabriella Martini
Journal:  Curr Ther Res Clin Exp       Date:  2004-09

6.  Nutritional support treatment for severe chronic hepatitis and posthepatitic cirrhosis.

Authors:  Huimin Qin; Hongtao Li; Mingyou Xing; Chunming Wu; Guojun Li; Jianxin Song
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

7.  Distinguishing between clinical and minimal hepatic encephalopathy on the basis of specific cognitive impairment.

Authors:  Katia Mattarozzi; Claudio Campi; Maria Guarino; Andrea Stracciari
Journal:  Metab Brain Dis       Date:  2005-09       Impact factor: 3.584

Review 8.  Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.

Authors:  Kavish R Patidar; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-09       Impact factor: 11.382

9.  Recovery from parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy.

Authors:  Josef Finsterer; Elisabeth Bernauer
Journal:  Metab Brain Dis       Date:  2005-03       Impact factor: 3.584

10.  Prognostic index of cirrhotic patients with hepatic encephalopathy with and without hepatocellular carcinoma.

Authors:  Keiichiro Yoneyama; Yuka Nebashi; Yuji Kiuchi; Minoru Shibata; Keiji Mitamura
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.